? BIOSPECIMEN SERVICES SHARED RESOURCE (BSSR) The mission of the BSSR is to support innovative translational research to advance the prevention, diagnosis, and treatment of cancer through the provision of biospecimens and clinical data.
The Specific Aims are to: 1) collect data and specimens from OSUCCC cancer patients using the IRB-approved Total Cancer Care (TCC) universal consenting and biobanking protocol for future unspecified research; 2) prospectively procure biospecimens for specific IRB-approved protocols; and 3) provide high quality, centralized biorepository services for IRB-approved, grant-funded and large institutional projects in a CAP-accredited biorepository. Over the current grant cycle, the major changes for the BSSR include: a) implementation of TCC across all Disease Specific Research Groups (DSRGs) covering all cancers - TCC now includes 57,256 consented subjects resulting in regular usage of biospecimens and data; and, b) the ORIEN AVATAR program was initiated, providing OSUCCC members with research grade next generation exome sequencing results on tumor and normal tissue with clinical annotation from 3,049 TCC subjects at OSU and 11,500 across ORIEN (the OSUCCC is a major contributor of samples). During the current grant cycle, the BSSR provided key services in support of 122 publications (35 > 10 impact factor), 105 users, and 24 NCI grants, including 1 K01, 1 K12, 2 P01s, 2 P50s, 11 R01s, 4 R21s, 1 U10, 1 UH2, and 1 UM1. Over the next grant cycle, BSSR will contribute to each of the new strategic priorities for the OSUCCC by providing biospecimens and high quality genomic and clinical data as requested by immuno-oncology, translational genomics, cancer engineering and cancer prevention and survivorship investigators. Each area will be supported by the TCC, and given the robust faculty recruitment and regularly increasing patient volumes; there will be an increase in prospective procurement and biobanking as well. Given the robust OSUCCC recruitment and increasing patient volumes, demand for services and new technologies will increase. The BBSR will expand its staff, instrumentation and services before capacity is reached. The annual budget of the BSSR is $2,206,277, yet the CCSG request is $179,168. As such, The BSSR leverages extensive institutional support and seeks only 8.1% support from CCSG funds.
|Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212|
|Qian, Maoxiang; Cao, Xueyuan; Devidas, Meenakshi et al. (2018) TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. J Clin Oncol 36:591-599|
|Myers, Regina M; Hill, Brian T; Shaw, Bronwen E et al. (2018) Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer 124:816-825|
|Nemeth, Julianna M; Thomson, Tiffany L; Lu, Bo et al. (2018) A social-contextual investigation of smoking among rural women: multi-level factors associated with smoking status and considerations for cessation. Rural Remote Health 18:4338|
|Mace, Thomas A; Shakya, Reena; Pitarresi, Jason R et al. (2018) IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67:320-332|
|Massengill, James B; Sample, Klarke M; Pilarski, Robert et al. (2018) Analysis of the exome aggregation consortium (ExAC) database suggests that the BAP1-tumor predisposition syndrome is underreported in cancer patients. Genes Chromosomes Cancer 57:478-481|
|Buteyn, Nathaniel J; Fatehchand, Kavin; Santhanam, Ramasamy et al. (2018) Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia. Int Immunol 30:375-383|
|Orchard, Tonya S; Andridge, Rebecca R; Yee, Lisa D et al. (2018) Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. J Acad Nutr Diet 118:578-588.e1|
|Reiff, Sean D; Mantel, Rose; Smith, Lisa L et al. (2018) The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer Discov 8:1300-1315|
|Pi, Fengmei; Binzel, Daniel W; Lee, Tae Jin et al. (2018) Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression. Nat Nanotechnol 13:82-89|
Showing the most recent 10 out of 2602 publications